Selected advances in tumor targeted anthracyclines

Carrier Conjugate Investigational or Approved Indications
Pegylated (Doxil - Caelyx) Ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma, high grade gliomas, glioblastoma or secondary brain tumors, head and neck squamous cell cancer, breast cancer, squamous cell carcinoma of the cervix
Uncoated, citrate-containing Breast cancer
[Evacet - Myocet (TLC D-99)]
Uncoated (DaunoXome) AIDS-related Kaposi's sarcoma, acute myeloblastic leukaemia, multiple myeloma, non-Hodgkin's lymphoma, breast cancer
Pegylated or uncoated Fab' fragments of trastuzumab Breast cancer
Pegylated anti-MUC-1 monoclonal antibody Breast cancer
Pegylated anti-CD19 monoclonal antibody Multiple myeloma
Pegylated Anti-GD(2) ganglioside whole antibodies Neuroblastoma
Pegylated Anti-aminopeptidase-N NGR peptide Neuroblastoma
Peptides or copolymers
L-377,202 N-glutaryl-[4-hydroxyprolyl]-Ala-Ser-cyclohexaglycyl-Glu-Ser-Leu Prostate cancer
CPI-0004Na (N-Succinyl-Ala-Ala-Leu) Breast cancer, prostate cancer
Uncoded Integrin-targeted RGD-4C peptide + plasmin-targeted (Ala-Phe-Lys) Fibrosarcoma
PK2 tetrapeptide linked to to galactosamine-containing N-(2-hydroxypropyl) methacrylamide copolymers Primary or metastatic liver cancer
  • All formulations contain DOX, except DaunoXome, which contains DNR.

    MUC-1, mucin-1 antigen.